PAYMENT OF NON-EXECUTIVE DIRECTORS' FEES IN SHARES

Oxford, UK, 5 February 2008 - Summit Corporation plc (AIM: SUMM) today announces that two Non-executive Directors of the Company have taken all or part of their fees for the quarter ended 31 January 2008 in ordinary shares pursuant to the Non-executive Share Ownership Scheme that came into effect on 1 February 2007.

The purchase of Summit ordinary shares was made on 5 February 2008 at a price of 90p per share. The number of shares purchased and the total holdings following these purchases of the Company's Non-executive Directors are shown below:

Non-executive Director	Number of ordinary shares purchased	Total holdings	Percentage of issued ordinary shares
Barry Price (Non-executive Chairman)	4,534	14,615	0.03%
George Elliott	2,164	5,291	0.01%

- ENDS -

For more information, please contact:

Summit plc Steven Lee, PhD, Chief Executive Officer Darren Millington, ACMA, Chief Financial Officer Richard Pye, PhD, Investor Relations	Tel: +44 (0)1235 443951
Citigate Dewe Rogerson Mark Swallow / David Dible	Tel: +44 (0)207 638 9571
Panmure Gordon Andrew Burnett / Rakesh Sharma	Tel: +44 (0)207 459 3600

About Summit plc

Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class expertise in both carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 - symbol: SUMM

Further information about the company is available at www.summitplc.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory condition.